Table 1.
Clinical and pathological features of adult B-ALL/LBL with isolated MYC translocation
| Prior and current reports | Age | Sex | Initial presentation | Treatment and Course | FISH(%) Cytogenetics |
BCL2 R BCL6 R |
CD10 | CD19 | CD20 | BCL-6 | CD34 | TdT | sIg | EBER |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Komrokji R, et al | 45 | M | B symptoms, splenomegaly | Hyper-CVAD alternating with high dose MTX/ARA-C | t(8,14)(q24,q32), +i(1)(q10) | NT | + | + | + | NT | − | − | − | NT |
| Shiratori S, et al | 64 | F | Choroid and skin involvement by B-LBL | Achieved CR after R-CHOP × 6; relapsed on skin 2 years later, achieved CR after radiation therapy; a further 2 years later, skin and choriod relapse as in initial stage | t(8;14)(q24;q32); positive IGH and TCR gene rearrangement | − | + | + | + | − | NT | + | NT | NT |
| Slavutsky I, et al | 20 | F | B symptoms, hepatomegaly, large retroperitoneal lymphadenopathy, and nephromegaly | n/a | t(8;22)(q24;q 11); hyperploid | NT | + | + | NT | NT | NT | NT | − | − |
| Li Y, et al | ||||||||||||||
| Case 1 | 70 | M | Diffuse lymphadnopathy, splenomegaly, PB and BM involvement | Hyper-CVAD and intrathecal methotrexate. Expired during the second cycle of chemotherapy | MYC/IGH (55%); 5q deleion (7/20) metaphases | − | + | + | − | − | − | + | + | − |
| Case 2 | 56 | M | Diffuse lymphadenopathy, hepatosplenomegaly, PB and BM involvment | High-risk ALL protocol (8707) with initial remission, but with progression two months after treatment. | MYC/IGH (60%) | − | + | + | − | − | − | −/+ | − | − |
| Case 3 | 44 | M | Bulky intrabdominal lymphadenopathy, negative BM | Hyper-CVAD with partial remission, pending stem cell transplant | MYC/IGH (63%) | − | + | NT | + | − | − | + | NT | − |
Abbreviations: NT, not tested; PB, peripheral blood; BM, bone marrow